Coherus Oncology announced interim clinical data from the TREGCHECK program for its investigational CCR8 antibody, tagmokitug. In evaluable first-line esophageal squamous cell carcinoma (ESCC) patients, tagmokitug combined with toripalimab and chemotherapy demonstrated a confirmed overall response rate of 75%, rising to 89% post-data cutoff. The company plans to expand enrollment in both first- and second-line ESCC cohorts based on these encouraging results and an acceptable safety profile. Coherus Oncology is a commercial-stage oncology company that markets the PD-1 inhibitor LOQTORZI and develops pipeline immunotherapy candidates for solid tumors.
